keyword
MENU ▼
Read by QxMD icon Read
search

prostate cancer, prognostic markers

keyword
https://www.readbyqxmd.com/read/28645312/phf21b-overexpression-promotes-cancer-stem-cell-like-traits-in-prostate-cancer-cells-by-activating-the-wnt-%C3%AE-catenin-signaling-pathway
#1
Qiji Li, Liping Ye, Wei Guo, Min Wang, Shuai Huang, Xinsheng Peng
BACKGROUND: PHF21B is newly identified to be involved in the tumor progression; however, its biological role and molecular mechanism in prostate cancer have not been defined. This study is aimed to study the role of PHF21B in the progression of prostate cancer. METHODS: Real-time PCR, immunohistochemistry and western blotting analysis were used to determine PHF21B expression in prostate cancer cell lines and clinical specimens. The role of PHF21B in maintaining prostate cancer stem cell-like phenotype was examined by tumor-sphere formation assay and expression levels of stem cell markers...
June 23, 2017: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/28628624/heterogeneity-of-mirna-expression-in-localized-prostate-cancer-with-clinicopathological-correlations
#2
Ahmed Hussein Zedan, Søren Garm Blavnsfeldt, Torben Frøstrup Hansen, Boye Schnack Nielsen, Niels Marcussen, Mindaugas Pleckaitis, Palle Jörn Sloth Osther, Flemming Brandt Sørensen
INTRODUCTION: In the last decade microRNAs (miRNAs) have been widely investigated in prostate cancer (PCa) and have shown to be promising biomarkers in diagnostic, prognostic and predictive settings. However, tumor heterogeneity may influence miRNA expression. The aims of this study were to assess the impact of tumor heterogeneity, as demonstrated by a panel of selected miRNAs in PCa, and to correlate miRNA expression with risk profile and patient outcome. MATERIAL AND METHODS: Prostatectomy specimens and matched, preoperative needle biopsies from a retrospective cohort of 49 patients, who underwent curatively intended surgery for localized PCa, were investigated with a panel of 6 miRNAs (miRNA-21, miRNA-34a, miRNA-125b, miRNA-126, miRNA-143, and miRNA-145) using tissue micro-array (TMA) and in situ hybridization (ISH)...
2017: PloS One
https://www.readbyqxmd.com/read/28618431/tumour-heterogeneity-poses-a-significant-challenge-to-cancer-biomarker-research
#3
Karolina Cyll, Elin Ersvær, Ljiljana Vlatkovic, Manohar Pradhan, Wanja Kildal, Marte Avranden Kjær, Andreas Kleppe, Tarjei S Hveem, Birgitte Carlsen, Silje Gill, Sven Löffeler, Erik Skaaheim Haug, Håkon Wæhre, Prasanna Sooriakumaran, Håvard E Danielsen
BACKGROUND: The high degree of genomic diversity in cancer represents a challenge for identifying objective prognostic markers. We aimed to examine the extent of tumour heterogeneity and its effect on the evaluation of a selected prognostic marker using prostate cancer as a model. METHODS: We assessed Gleason Score (GS), DNA ploidy status and phosphatase and tensin homologue (PTEN) expression in radical prostatectomy specimens (RP) from 304 patients followed for a median of 10 years (interquartile range 6-12)...
June 15, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28618396/vitamin-d-receptor-binding-site-variants-affect-prostate-cancer-progression
#4
Victor C Lin, Shu-Pin Huang, Huei-Ju Ting, Wen-Lung Ma, Chia-Cheng Yu, Chao-Yuan Huang, Hsin-Ling Yin, Tsung-Yi Huang, Cheng-Hsueh Lee, Ta-Yuan Chang, Te-Ling Lu, Bo-Ying Bao
Vitamin D is an important modulator of cellular proliferation through the vitamin D receptor (VDR) that binds to DNA in the regulatory sequences of target genes. We hypothesized that single nucleotide polymorphisms (SNPs) in VDR-binding sites might affect target gene expression and influence the progression of prostate cancer. Using a genome-wide prediction database, 62 SNPs in VDR-binding sites were selected for genotyping in 515 prostate cancer patients and the findings were replicated in an independent cohort of 411 patients...
May 26, 2017: Oncotarget
https://www.readbyqxmd.com/read/28591719/stable-and-high-expression-of-galectin-8-tightly-controls-metastatic-progression-of-prostate-cancer
#5
Lucas Daniel Gentilini, Felipe Martín Jaworski, Carolina Tiraboschi, Ignacio González Pérez, Monica Lidia Kotler, Anne Chauchereau, Diego Jose Laderach, Daniel Compagno
Two decades ago, Galectin-8 was described as a prostate carcinoma biomarker since it is only expressed in the neoplastic prostate, but not in the healthy tissue. To date, no biological function has been attributed to Galectin-8 that could explain this differential expression. In this study we silenced Galectin-8 in two human prostate cancer cell lines, PC3 and IGR-CaP1, and designed a pre-clinical experimental model that allows monitoring the pathology from its early steps to the long-term metastatic stages...
May 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28589907/improving-circulating-tumor-cells-enumeration-and-characterization-to-predict-outcome-in-first-line-chemotherapy-mcrpc-patients
#6
Luis León-Mateos, Helena Casas, Alicia Abalo, María Vieito, Manuel Abreu, Urbano Anido, Antonio Gómez-Tato, Rafael López, Miguel Abal, Laura Muinelo-Romay
INTRODUCTION: There is a critical need of new surrogate markers for improving the therapeutic selection and monitoring of metastatic prostate cancer patients. Nowadays clinical management of these patients is been driven by biochemical and clinical parameters without enough accuracy to allow a real personalized medicine. The present study was conducted to go insight the molecular profile of circulating tumor cells (CTCs) isolated from advanced metastatic castration-resistant prostate cancer (mCRPC) with the aim of identifying prognostic marker with potential utility for therapy selection and monitoring...
May 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28560739/predictive-value-of-different-prostate-specific-antigen-based-markers-in-men-with-baseline-total-prostate-specific-antigen-2-0-ng-ml
#7
Yuji Fujizuka, Kazuto Ito, Ryo Oki, Rie Suzuki, Yoshitaka Sekine, Hidekazu Koike, Hiroshi Matsui, Yasuhiro Shibata, Kazuhiro Suzuki
OBJECTIVES: To investigate the predictive value of various molecular forms of prostate-specific antigen in men with baseline prostate-specific antigen <2.0 ng/mL. METHODS: The case cohort comprised 150 men with a baseline prostate-specific antigen level <2.0 ng/mL, and who developed prostate cancer within 10 years. The control cohort was 300 baseline prostate-specific antigen- and age-adjusted men who did not develop prostate cancer. Serum prostate-specific antigen, free prostate-specific antigen, and [-2] proenzyme prostate-specific antigen were measured at baseline and last screening visit...
May 31, 2017: International Journal of Urology: Official Journal of the Japanese Urological Association
https://www.readbyqxmd.com/read/28560449/hypoxia-induced-angiopoietin-like-protein-4-as-a-clinical-biomarker-and-treatment-target-for-human-prostate-cancer
#8
Shinro Hata, Takeo Nomura, Kazunori Iwasaki, Ryuta Sato, Mutsushi Yamasaki, Fuminori Sato, Hiromitsu Mimata
Angiopoietin-like protein 4 (ANGPTL4) is a multifunctional protein, playing roles in glucose and lipid metabolism, inflammation, angiogenesis, and tumorigenesis. Recent research suggests that ANGPTL4 is induced by hypoxia and is a useful diagnostic or prognostic marker for various cancers. However, it remains unclear whether ANGPTL4 expression influences prostate cancer. Here we examined the biological and clinical relevance of ANGPTL4 expression in prostate cancer. Firstly we examined ANGPTL4 expression in the prostate cancer cell lines LNCaP and LNCaP/CH incubated at 1% O2 for at least 6 months...
May 24, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28546759/predictive-significance-of-hmgcs2-for-prognosis-in-resected-chinese-esophageal-squamous-cell-carcinoma-patients
#9
Hong Tang, Yufeng Wu, Yanru Qin, Hongyan Wang, Yongxu Jia, Shujun Yang, Suxia Luo, Qiming Wang
Despite a series of attempts during the last decades, the prognosis of esophageal squamous cell carcinoma (ESCC) remains poor. Different responses of individual tumors encouraged us to look for valuable prognostic markers. As a key regulator controlling the anabolic ketogenic pathway, 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2) has been reported to play a crucial role in colorectal cancer and prostate cancer. However, its importance to ESCC has not been verified. Therefore, a large cohort retrospective study was planned, to investigate the relationship between HMGCS2 expression and ESCC prognosis...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28545426/insulin-like-growth-factor-1-receptor-affects-the-survival-of-primary-prostate-cancer-patients-depending-on-tmprss2-erg-status
#10
Caterina Mancarella, Irene Casanova-Salas, Ana Calatrava, Maria García-Flores, Cecilia Garofalo, Andrea Grilli, José Rubio-Briones, Katia Scotlandi, José Antonio López-Guerrero
BACKGROUND: Prostate cancer (PCa) is characterized by clinical and biological heterogeneity and has differential outcomes and mortality rates. Therefore, it is necessary to identify molecular alterations to define new therapeutic strategies based on the risk of progression. In this study, the prognostic relevance of the insulin-like growth factor (IGF) system was examined in molecular subtypes defined by TMPRSS2-ERG (T2E) gene fusion within a series of patients with primary localized PCa...
May 25, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28525899/the-prognostic-value-of-long-noncoding-rnas-in-prostate-cancer-a-systematic-review-and-meta-analysis
#11
Weijie Ma, Xi Chen, Lu Ding, Jianhong Ma, Wei Jing, Tian Lan, Haseeb Sattar, Yongchang Wei, Fuling Zhou, Yufeng Yuan
The abnormally expressed LncRNAs played irreplaceable roles in the prognosis of prostate cancer (PCa). Therefore, we conducted this systematic review and meta-analysis to summarize the association between the expression of LncRNAs, prognosis and clinicopathology of PCa. 18 eligible studies were recruited into our analysis, including 18 on prognosis and 9 on clinicopathological features. Results indicated that aberrant expression of LncRNAs was significantly associated with biochemical recurrence-free survival (BCR-FS) (HR = 1...
May 7, 2017: Oncotarget
https://www.readbyqxmd.com/read/28521303/emt-circulating-tumor-cells-detected-by-cell-surface-vimentin-are-associated-with-prostate-cancer-progression
#12
Arun Satelli, Izhar Batth, Zachary Brownlee, Abhishek Mitra, Shouhao Zhou, Hyangsoon Noh, Christina R Rojas, Heming Li, Qing H Meng, Shulin Li
Recent advances in the field of circulating tumor cells (CTC) have shown promise in this liquid biopsy-based prognosis of patient outcome. However, not all of the circulating cells are tumor cells, as evidenced by a lack of tumor-specific markers. The current FDA standard for capturing CTCs (CellSearch) relies on an epithelial marker and cells captured via CellSearch cannot be considered to have undergone EMT. Therefore, it is difficult to ascertain the presence and relevance of any mesenchymal or EMT-like CTCs...
May 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28515807/external-validation-of-the-procars-nomograms-and-comparison-of-existing-risk-stratification-tools-for-localized-prostate-cancer
#13
David Tiberi, George Rodrigues, Tom Pickles, Jim Morris, Juanita Crook, Andre-Guy Martin, Fabio Cury, Charles Catton, Himu Lukka, Andrew Warner, Daniel Taussky
INTRODUCTION: The purpose of this study was to perform a direct comparison of several existing risk-stratification tools for localized prostate cancer in terms of their ability to predict for biochemical failure-free survival (BFFS). Two large databases were used and an external validation of two recently developed nomograms on an independent cohort was also performed in this analysis. METHODS: Patients who were treated with external beam radiotherapy (EBRT) and/or brachytherapy for localized prostate cancer were selected from the multi-institutional Genitourinary Radiation Oncologists of Canada (GUROC) Prostate Cancer Risk Stratification (ProCaRS) database (n=7974) and the Centre Hospitalier de l'Université de Montréal (CHUM) validation database (n=2266)...
March 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28494073/associations-of-luminal-and-basal-subtyping-of-prostate-cancer-with-prognosis-and-response-to-androgen-deprivation-therapy
#14
Shuang G Zhao, S Laura Chang, Nicholas Erho, Menggang Yu, Jonathan Lehrer, Mohammed Alshalalfa, Corey Speers, Matthew R Cooperberg, Won Kim, Charles J Ryan, Robert B Den, Stephen J Freedland, Edwin Posadas, Howard Sandler, Eric A Klein, Peter Black, Roland Seiler, Scott A Tomlins, Arul M Chinnaiyan, Robert B Jenkins, Elai Davicioni, Ashley E Ross, Edward M Schaeffer, Paul L Nguyen, Peter R Carroll, R Jeffrey Karnes, Daniel E Spratt, Felix Y Feng
Importance: There is a clear need for a molecular subtyping approach in prostate cancer to identify clinically distinct subgroups that benefit from specific therapies. Objectives: To identify prostate cancer subtypes based on luminal and basal lineage and to determine associations with clinical outcomes and response to treatment. Design, Setting, and Participants: The PAM50 classifier was used to subtype 1567 retrospectively collected (median follow-up, 10 years) and 2215 prospectively collected prostate cancer samples into luminal- and basal-like subtypes...
May 11, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28486040/gata2-expression-and-biochemical-recurrence-following-salvage-radiation-therapy-for-relapsing-prostate-cancer
#15
Jessica L Robinson, Katherine S Tzou, Alexander S Parker, Michael G Heckman, Kevin J Wu, Tracy W Hilton, Thomas M Pisansky, Steven E Schild, Jennifer L Peterson, Laura A Vallow, Steven J Buskirk
OBJECTIVES: High GATA2 expression has been associated with an increased risk of poor clinical outcomes after radical prostatectomy (RP), however has not been studied in relation to risk of biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer after RP. Our aim was to evaluate the association between protein expression levels of GATA2 in primary prostate cancer tumor samples and risk of BCR after SRT. METHODS: 109 men who were treated with SRT were included...
May 9, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28484728/pretreatment-prostate-specific-antigen-doubling-time-as-prognostic-factor-in-prostate-cancer-patients
#16
Gennady M Zharinov, Oleg A Bogomolov, Natalia N Neklasova, Vladimir N Anisimov
Despite the prostate-specific antigen (PSA) serum level commonly uses as tumor marker in diagnosis of prostate cancer, it seems that PSA doubling time (PSADT) could be more useful indicator of tumor behavior and of prognosis for patients. The results of hormone and radiation therapy were evaluated for 912 prostate cancer having at least 2 PSA tests before the treatment was started. Clustering procedure (selection of homogenous group) was performed by using PSADT as the classification marker. The rate of PSADT was estimated for different dissemination rate, age, Gleasons's score and education level...
January 2017: Oncoscience
https://www.readbyqxmd.com/read/28479874/prognostic-correlation-of-cell-cycle-progression-score-and-ki-67-as-a-predictor-of-aggressiveness-biochemical-failure-and-mortality-in-men-with-high-risk-prostate-cancer-treated-with-external-beam-radiation-therapy
#17
Iván Henríquez López, David Parada, Pablo Gallardo, Marina Gascón, Arnau Besora, Karla Peña, Francesc Riu, Miquel Arquez Pianetta, Oscar Abuchaibe, Laura Torres Royò, Meritxell Arenas
OBJECTIVES: Ki-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness. The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT). METHODS: CCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006...
May 2017: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/28476530/enriching-gene-expression-profiles-will-help-personalize-prostate-cancer-management-for-african-americans-a-perspective
#18
REVIEW
Srinivasan Vijayakumar, John C Henegan, Xu Zhang, Wanmei Wang, William A Day, Vani Vijayakumar, Carlos S Moreno, Christian R Gomez
Prostate cancer (PCa) remains the most common form of cancer affecting men in the Western Hemisphere. Mortality rate is 130% higher among African-American men (AAM) than Caucasian-American men. As this trend is not new nor changing, there is an urgent need to identify markers with the ability to specifically distinguish aggressive PCa in the context of race. Gene expression patterns have been used as a tool to identify prognostic biomarkers for PCa to help reduce this disparity. Gene expression profiles reveal molecular mechanisms useful in understanding the biologic basis of tumorigenesis...
June 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28475401/cellular-identity-crisis-antiandrogen-resistance-by-lineage-plasticity
#19
Daniel Tuerff, Tristan Sissung, William D Figg
A recent publication in Science demonstrates the ability of prostate cancer cells to switch lineages from one that is dependent on androgen signaling to a cell type that is not. Known as lineage plasticity, this phenomenon is driven by the transcription factor SOX2 in RB1 and TP53-deficient prostate cancer. SOX2 is a potential prognostic marker and therapeutic target in castration resistant prostate cancer.
May 5, 2017: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/28469484/preoperative-serum-carcinoembryonic-antigen-as-a-marker-for-predicting-the-outcome-of-three-cancers
#20
Jingzhu Nan, Juan Li, Xiujuan Li, Guanghong Guo, Xinyu Wen, Yaping Tian
BACKGROUND: Serum levels of carcinoembryonic antigen (CEA) are associated with a variety of tumors. OBJECTIVE: This study evaluated the prognostic value of pretreatment serum CEA levels in predicting the outcomes of multiple tumors subjected to treatment. METHODS: Prior to therapy, serum samples from 71 prostate, 46 breast, 77 gastric, and 31 pancreatic cancer patients were collected to examine serum CEA levels. The cutoff value for CEA was set as determined by the maximum Youden index...
2017: Biomarkers in Cancer
keyword
keyword
98461
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"